The Journal of clinical endocrinology and metabolism最新文献

{"title":"Hypothyroidism in Danish pregnant women across decades.","authors":"Marco Juul Thomsen, Nanna Maria Uldall Torp, Allan Carlé, Jesper Karmisholt, Inge Bülow Pedersen, Stig Andersen, Stine Linding Andersen","doi":"10.1210/clinem/dgaf300","DOIUrl":"https://doi.org/10.1210/clinem/dgaf300","url":null,"abstract":"<p><strong>Context: </strong>Iodine fortification programs have been implemented worldwide, and concerns are raised on an increase in autoimmune hypothyroidism following the increase in population iodine intake.</p><p><strong>Objective: </strong>To study the consecutive occurrence of hypothyroidism in Danish pregnant women across decades starting before the nationwide iodine fortification of salt implemented in the year of 2000.</p><p><strong>Methods: </strong>Nationwide register-based study of pregnant women in Denmark, 1997-2016, who carried a singleton, live-born pregnancy (n = 1,189,134). The geographical residence was used as a proxy of iodine intake, and the cohort was stratified by East (n = 549,410), with previously mild iodine deficiency, and West Denmark (n = 639,724), with previously moderate iodine deficiency. Information on maternal hypothyroidism was assessed from redeemed prescriptions of Levothyroxine and reported as incidence and prevalence in pregnancy.</p><p><strong>Results: </strong>In 1997, three years prior to iodine fortification, the incidence of maternal hypothyroidism in pregnancy in East was 0.55/1,000 pregnancies (95% confidence interval (CI): 0.30-0.93) and 0.48/1,000 pregnancies (95% CI: 0.27-0.77) in West Denmark. The incidence increased in both cohorts and at the end of follow-up (the year 2016), it was 9.1 (95% CI: 8.0-10.3) in East and 5.1 (95% CI: 4.3-6.0)/1,000 pregnancies in West Denmark. Similarly, the prevalence of hypothyroidism in pregnancy had increased (1997-1999: East 3.8 and West 3.1/1,000 pregnancies; 2013-2016: East 24.5 and West 15.8/1,000 pregnancies).</p><p><strong>Conclusions: </strong>When evaluated in a large nationwide cohort across decades, the occurrence of hypothyroidism in Danish pregnant women increased. Regional differences were found and encourage further studies on the underlying mechanisms.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of Hot Flash Management in Patients with Prostate Cancer.","authors":"Kevin Lawrence Lin, Barak Talmor, Megan Crumbaker, Anthony Joshua","doi":"10.1210/clinem/dgaf302","DOIUrl":"https://doi.org/10.1210/clinem/dgaf302","url":null,"abstract":"<p><strong>Context: </strong>Vasomotor symptoms (VMS) including hot flashes are a common toxicity reported by men undergoing androgen deprivation therapy (ADT) and their effective mitigation remains crucial in prostate cancer survivorship. As the understanding of hot flash pathophysiology is refined, novel therapies offer promising benefits to this patient cohort.</p><p><strong>Evidence acquisition: </strong>The following mini-review outlines the landscape of VMS management in patients with prostate cancer as informed by a literature search using the PubMed and Embase databases.</p><p><strong>Evidence synthesis: </strong>Hormonal therapies appear most effective for ameliorating VMS in men with prostate cancer experiencing bothersome hot flashes. Transdermal oestradiol has been well-validated, with recent evidence hinting at its promise as an alternative form of ADT that mitigates VMS. Nonhormonal treatments proven to be efficacious include gabapentin, oxybutynin and various antidepressants although their utility can be limited by adverse effects. There is significant interest in novel agents like fezolinetant that target hypothalamic thermoregulatory pathways, however further validation in this cohort is required. Nonpharmacological options including cognitive behaviour therapy and acupuncture may also have a role although further research is needed to clarify the optimal schedule and confirm superiority over placebo.</p><p><strong>Conclusion: </strong>Clinicians should be prepared to offer evidence-based management options for the detrimental effects of ADT. Proven therapies for VMS including oxybutynin and antidepressants may soon be complemented by neurokinin antagonists which currently boast great efficacy for menopausal hot flashes. Hormonal options like transdermal oestrogen are most likely to provide relief but gynaecomastia may develop.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Sex Hormones in Mediating Adiposity Changes from Weight Loss in People with Type 2 Diabetes: Look AHEAD Sex Hormone Study.","authors":"Chigolum P Oyeka, Jiahuan Helen He, Jianqiao Ma, Erin D Michos, Rita R Kalyani, Mark Woodward, Dhananjay Vaidya, Wendy L Bennett","doi":"10.1210/clinem/dgaf287","DOIUrl":"https://doi.org/10.1210/clinem/dgaf287","url":null,"abstract":"<p><strong>Background: </strong>In people with type 2 diabetes (T2D), weight loss impacts sex hormones (testosterone [T], estradiol [E2], sex hormone binding globulin [SHBG]) and reduces fat and lean mass differently in females vs males, but the relationship between sex hormones and adiposity changes due to weight loss is not clear.</p><p><strong>Methods: </strong>We analyzed data from 2,334 participants (50% female) in the Look AHEAD Sex Hormone Ancillary Study, including a subset of 822 (47.4% female) with dual-energy X-ray absorptiometry scans. Using structural equation modeling, we assessed how changes in E2, T, and SHBG at year 1 (Y1) mediated the effects of intensive lifestyle intervention (ILI) on adiposity measures at year 4 (Y4). We stratified by sex to explore sex differences.</p><p><strong>Results: </strong>In males, a 14.4% ILI-associated increase in total T at Y1 mediated increases in weight (189g, 95% CI: 65g-317g) and waist circumference (0.135cm, 95% CI: 0.19-0.248cm) at Y4. Additionally, a 24.6% increase in SHBG at Y1 mediated increases in both % trunk fat (0.082%, 95% CI: 0.003%-0.174%) and % whole-body fat (0.068%, 95% CI: 0.001%-0.146%) at Y4. In females, a 21.8% decrease in bioavailable testosterone (BioT) at Y1 mediated decreases in whole-body fat mass (-164g, 95% CI: -326g to -29.3g), whole-body lean mass (-115g, 95% CI: -203.4g to -40g), and trunk lean mass (-97.2g, 95% CI: -156g to -45.5g) at Y4.</p><p><strong>Conclusion: </strong>The study revealed sex-specific mediating effects of sex hormones due to weight loss from ILI on body composition changes in people with T2D. Further research is needed to explore long-term health outcomes related to sex differences in recommendations for weight loss in people with T2D.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative and Quantitative Analyses of Noninvasive Diagnosis of Insulinoma Using [18F]FB(ePEG12) 12-Exendin-4 PET/CT.","authors":"Takaaki Murakami, Hayao Yoshida, Kentaro Sakaki, Daisuke Otani, Kanae Kawai Miyake, Yoichi Shimizu, Hiroyuki Fujimoto, Daisuke Yabe, Yuji Nakamoto, Nobuya Inagaki","doi":"10.1210/clinem/dgaf253","DOIUrl":"https://doi.org/10.1210/clinem/dgaf253","url":null,"abstract":"<p><strong>Context: </strong>This study represents the first interim report from a phase 2 clinical trial. Accurate localization of insulinomas remains a clinical challenge despite the availability of various imaging modalities.</p><p><strong>Objective: </strong>The current study aimed to evaluate the efficacy of positron emission tomography/computed tomography (PET/CT) using [18F]FB(ePEG12)12-exendin-4 (18F-exendin-4), a novel 18F-labeled PEGylated glucagon-like peptide 1 (GLP-1) receptor-targeted imaging probe, for the noninvasive detection of insulinomas.</p><p><strong>Methods: </strong>This prospective single-center study enrolled patients with biochemically confirmed hyperinsulinemic hypoglycemia suggestive of insulinoma. All patients underwent 18F-exendin-4 PET/CT, with scans performed at 60 and 120 minutes after injection. The findings of 18F-exendin-4 PET/CT were then compared with those of conventional imaging modalities performed before and after 18F-exendin-4 PET/CT in actual clinical settings, with all findings being verified through surgical and pathological findings.</p><p><strong>Results: </strong>18F-exendin-4 PET/CT successfully identified insulinomas in all 12 patients (100% sensitivity), showing significantly higher uptake in tumor tissues than in the surrounding pancreatic tissues and organs. The detection rate of 18F-exendin-4 PET/CT exceeded that of the conventional imaging modalities (CT, 83%; magnetic resonance imaging, 63%; endoscopic ultrasonography, 90%; selective arterial calcium stimulation, 89%). All identified lesions were surgically confirmed to be insulinomas, with complete clinical resolution of hypoglycemia after resection.</p><p><strong>Conclusion: </strong>18F-exendin-4 PET/CT demonstrated effective sensitivity for noninvasive insulinoma detection, offering a reliable and practical diagnostic alternative to invasive procedures for precise and prompt preoperative localization with functional evaluation. This novel imaging approach may therefore improve the management of patients with suspected insulinomas.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Localization of benign insulinomas with a radionuclide tracer targeting the GLP-1 receptor with pegylated exendin-4.","authors":"Michael A Nauck, Waldemar Uhl","doi":"10.1210/clinem/dgaf297","DOIUrl":"https://doi.org/10.1210/clinem/dgaf297","url":null,"abstract":"","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.","authors":"Neal Pohlman, Prem N Patel, Utibe R Essien, Jasmyn J Tang, Joshua J Joseph","doi":"10.1210/clinem/dgaf295","DOIUrl":"https://doi.org/10.1210/clinem/dgaf295","url":null,"abstract":"<p><p>Cardiovascular-kidney-metabolic (CKM) syndrome represents a complex interplay of obesity, hypertension, hyperlipidemia, type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and cardiovascular disease (CVD), driving elevated morbidity and mortality. CKM syndrome encompasses a continuum of interrelated metabolic, renal, and cardiovascular dysfunctions attributed to obesity, impaired glucose regulation, and chronic inflammation. This review synthesizes recent literature on the efficacy of cardiorenal protective medications including sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) in CKM syndrome management. SGLT2i agents show promising outcomes, including reduced cardiovascular mortality, hospitalization for heart failure, and adverse kidney events across diverse patient populations, regardless of T2DM status. Similarly, GLP-1RA agents demonstrate substantial benefits in weight loss, glycemic control, and reduced cardiovascular and kidney events. The review also highlights the necessity of equitable pharmacotherapy distribution to ensure that high-risk populations benefit from these advancements and the need for further precision-based therapeutic frameworks, policy innovations, and tailored interventions focused on CKM syndrome management. Finally, we discuss strategies for translating these findings into practice through an equity-focused lens to advance CKM health.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive tests developed using artificial intelligence for screening in MASLD: interest and pitfalls.","authors":"Jerome Boursier, Bertrand Cariou","doi":"10.1210/clinem/dgaf294","DOIUrl":"https://doi.org/10.1210/clinem/dgaf294","url":null,"abstract":"","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Islet Autoantibody Level Distribution in Type 1 Diabetes and Their Association With Genetic and Clinical Characteristics.","authors":"Sian Louise Grace,&nbsp;Jack Bowden,&nbsp;Helen C Walkey,&nbsp;Akaal Kaur,&nbsp;Shivani Misra,&nbsp;Beverley M Shields,&nbsp;Trevelyan J McKinley,&nbsp;Nick S Oliver,&nbsp;Timothy J McDonald,&nbsp;Desmond G Johnston,&nbsp;Angus G Jones,&nbsp;Kashyap A Patel","doi":"10.1210/clinem/dgac507","DOIUrl":"https://doi.org/10.1210/clinem/dgac507","url":null,"abstract":"<p><strong>Context: </strong>The importance of the autoantibody level at diagnosis of type 1 diabetes (T1D) is not clear.</p><p><strong>Objective: </strong>We aimed to assess the association of glutamate decarboxylase (GADA), islet antigen-2 (IA-2A), and zinc transporter 8 (ZnT8A) autoantibody levels with clinical and genetic characteristics at diagnosis of T1D.</p><p><strong>Methods: </strong>We conducted a prospective, cross-sectional study. GADA, IA-2A, and ZnT8A were measured in 1644 individuals with T1D at diagnosis using radiobinding assays. Associations between autoantibody levels and the clinical and genetic characteristics for individuals were assessed in those positive for these autoantibodies. We performed replication in an independent cohort of 449 people with T1D.</p><p><strong>Results: </strong>GADA and IA-2A levels exhibited a bimodal distribution at diagnosis. High GADA level was associated with older age at diagnosis (median 27 years vs 19 years, P = 9 × 10-17), female sex (52% vs 37%, P = 1 × 10-8), other autoimmune diseases (13% vs 6%, P = 3 × 10-6), and HLA-DR3-DQ2 (58% vs 51%, P = .006). High IA-2A level was associated with younger age of diagnosis (median 17 years vs 23 years, P = 3 × 10-7), HLA-DR4-DQ8 (66% vs 50%, P = 1 × 10-6), and ZnT8A positivity (77% vs 52%, P = 1 × 10-15). We replicated our findings in an independent cohort of 449 people with T1D where autoantibodies were measured using enzyme-linked immunosorbent assays.</p><p><strong>Conclusion: </strong>Islet autoantibody levels provide additional information over positivity in T1D at diagnosis. Bimodality of GADA and IA-2A autoantibody levels highlights the novel aspect of heterogeneity of T1D. This may have implications for T1D prediction, treatment, and pathogenesis.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":"e4341-e4349"},"PeriodicalIF":5.8,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33448993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peptide Receptor Radionuclide Therapy.","authors":"Johannes Hofland,&nbsp;Tessa Brabander,&nbsp;Frederik A Verburg,&nbsp;Richard A Feelders,&nbsp;Wouter W de Herder","doi":"10.1210/clinem/dgac574","DOIUrl":"https://doi.org/10.1210/clinem/dgac574","url":null,"abstract":"Abstract The concept of using a targeting molecule labeled with a diagnostic radionuclide for using positron emission tomography or single photon emission computed tomography imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule labeled with a therapeutic radionuclide termed “theranostics.” Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs (SSAs) is a well-established second/third-line theranostic treatment for somatostatin receptor-positive well-differentiated (neuro-)endocrine neoplasms (NENs). PRRT with 177Lu-DOTATATE was approved by the regulatory authorities in 2017 and 2018 for selected patients with low-grade well-differentiated gastroenteropancreatic (GEP) NENs. It improves progression-free survival as well as quality of life of GEP NEN patients. Favorable symptomatic and biochemical responses using PRRT with 177Lu-DOTATATE have also been reported in patients with functioning metastatic GEP NENs like metastatic insulinomas, Verner Morrison syndromes (VIPomas), glucagonomas, and gastrinomas and patients with carcinoid syndrome. This therapy might also become a valuable therapeutic option for inoperable low-grade bronchopulmonary NENs, inoperable or progressive pheochromocytomas and paragangliomas, and medullary thyroid carcinomas. First-line PRRT with 177Lu-DOTATATE and combinations of this therapy with cytotoxic drugs are currently under investigation. New radiolabeled somatostatin receptor ligands include SSAs coupled with alpha radiation emitting radionuclides and somatostatin receptor antagonists coupled with radionuclides.","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":"3199-3208"},"PeriodicalIF":5.8,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33488895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes.","authors":"Sebastian Møller Nguyen Heimbürger,&nbsp;Bjørn Hoe,&nbsp;Chris Neumann Nielsen,&nbsp;Natasha Chidekel Bergman,&nbsp;Kirsa Skov-Jeppesen,&nbsp;Bolette Hartmann,&nbsp;Jens Juul Holst,&nbsp;Flemming Dela,&nbsp;Julie Overgaard,&nbsp;Joachim Størling,&nbsp;Tina Vilsbøll,&nbsp;Thomas Fremming Dejgaard,&nbsp;Jesper Foged Havelund,&nbsp;Vladimir Gorshkov,&nbsp;Frank Kjeldsen,&nbsp;Nils Joakim Færgeman,&nbsp;Martin Rønn Madsen,&nbsp;Mikkel B Christensen,&nbsp;Filip Krag Knop","doi":"10.1210/clinem/dgac542","DOIUrl":"https://doi.org/10.1210/clinem/dgac542","url":null,"abstract":"<p><strong>Context: </strong>Glucose-dependent insulinotropic polypeptide (GIP) has been proposed to exert insulin-independent effects on lipid and bone metabolism.</p><p><strong>Objective: </strong>We investigated the effects of a 6-day subcutaneous GIP infusion on circulating lipids, white adipose tissue (WAT), brown adipose tissue (BAT), hepatic fat content, inflammatory markers, respiratory exchange ratio (RER), and bone homeostasis in patients with type 1 diabetes.</p><p><strong>Methods: </strong>In a randomized, placebo-controlled, double-blind, crossover study, 20 men with type 1 diabetes underwent a 6-day continuous subcutaneous infusion with GIP (6 pmol/kg/min) and placebo (saline), with an interposed 7-day washout period.</p><p><strong>Results: </strong>During GIP infusion, participants (26 ± 8 years [mean ± SD]; BMI 23.8 ± 1.8 kg/m2; glycated hemoglobin A1c 51 ± 10 mmol/mol [6.8 ± 3.1%]) experienced transiently increased circulating concentrations of nonesterified fatty acid (NEFA) (P = 0.0005), decreased RER (P = 0.009), indication of increased fatty acid β-oxidation, and decreased levels of the bone resorption marker C-terminal telopeptide (P = 0.000072) compared with placebo. After 6 days of GIP infusion, hepatic fat content was increased by 12.6% (P = 0.007) and supraclavicular skin temperature, a surrogate indicator of BAT activity, was increased by 0.29 °C (P < 0.000001) compared with placebo infusion. WAT transcriptomic profile as well as circulating lipid species, proteome, markers of inflammation, and bone homeostasis were unaffected.</p><p><strong>Conclusion: </strong>Six days of subcutaneous GIP infusion in men with type 1 diabetes transiently decreased bone resorption and increased NEFA and β-oxidation. Further, hepatic fat content, and supraclavicular skin temperature were increased without affecting WAT transcriptomics, the circulating proteome, lipids, or inflammatory markers.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":"3261-3274"},"PeriodicalIF":5.8,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40363284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}